Article
A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.
Genes and immunity - 1 Jun 2025
Almeida Marcio A, Diego Vincent P, Viel Kevin R, Luu Bernadette W, Haack Karin, Rajalingam Raja, Ameri Afshin, Chitlur Meera, Rydz Natalia, Lillicrap David, Watts Raymond G, Kessler Craig M, Ramsey Christopher, Dinh Long V, Kim Benjamin, Powell Jerry S, Manusov Eron G, Peralta Juan M, Bouls Ruayda, Abraham Shirley M, Shen Yu-Min, Murillo Carlos M, Mead Henry, Lehmann Paul V, Fine Eli J, Escobar Miguel A, Kumar Satish, Konkle Barbara A, Williams-Blangero Sarah, Kasper Carol K, Almasy Laura, Cole Shelley A, Blangero John, Howard Tom E
Abstract excerpt
Hemophilia-A (HA) is the X-linked bleeding disorder caused by heterogeneous factor (F)VIII gene (F8)-mutations and deficiencies in plasma-FVIII-activity that prevent intrinsic-pathway mediated coagulation-amplification. Severe-HA patients (HAPs) require life-long infusions of therapeutic-FVIII-proteins (tFVIIIs) but ~30% develop neutralizing-tFVIII-antibodies called "FVIII-inhibitors (FEIs)". We investigated the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
